SMAD4–dependent barrier constrains prostate cancer growth and metastatic progression
View/ Open
Author
Ding, Zhihu
Wu, Chang–Jiun
Chu, Gerald C.
Xiao, Yonghong
Ho, Dennis
Zhang, Jingfang
Perry, Samuel R.
Labrot, Emma S.
Wu, Xiaoqiu
Lis, Rosina
Hoshida, Yujin
Hiller, David
Hu, Baoli
Jiang, Shan
Zheng, Hongwu
Stegh, Alexander H.
Scott, Kenneth L.
Signoretti, Sabina
Bardeesy, Nabeel
Wang, Y. Alan
Hill, David E.
Golub, Todd R.
Wong, Wing H.
Loda, Massimo
Mucci, Lorelei
Chin, Lynda
DePinho, Ronald A.
Published Version
https://doi.org/10.1038/nature09677Metadata
Show full item recordCitation
Ding, Zhihu, Chang-Jiun Wu, Gerald C. Chu, Yonghong Xiao, Dennis Ho, Jingfang Zhang, Samuel R. Perry, et al. 2011. “SMAD4-Dependent Barrier Constrains Prostate Cancer Growth and Metastatic Progression.” Nature 470 (7333): 269–73. https://doi.org/10.1038/nature09677.Abstract
Effective clinical management of prostate cancer (PCA) has been challenged by significant intratumoural heterogeneity on the genomic and pathological levels and limited understanding of the genetic elements governing disease progression(1). Here, we exploited the experimental merits of the mouse to test the hypothesis that pathways constraining progression might be activated in indolent Pten-null mouse prostate tumours and that inactivation of such progression barriers in mice would engender a metastasis-prone condition. Comparative transcriptomic and canonical pathway analyses, followed by biochemical confirmation, of normal prostate epithelium versus poorly progressive Pten-null prostate cancers revealed robust activation of the TGF beta/BMP-SMAD4 signalling axis. The functional relevance of SMAD4 was further supported by emergence of invasive, metastatic and lethal prostate cancers with 100% penetrance upon genetic deletion of Smad4 in the Pten-null mouse prostate. Pathological and molecular analysis as well as transcriptomic knowledge-based pathway profiling of emerging tumours identified cell proliferation and invasion as two cardinal tumour biological features in the metastatic Smad4/Pten-null PCA model. Follow-on pathological and functional assessment confirmed cyclin D1 and SPP1 as key mediators of these biological processes, which together with PTEN and SMAD4, form a four-gene signature that is prognostic of prostate-specific antigen (PSA) biochemical recurrence and lethal metastasis in human PCA. This model-informed progression analysis, together with genetic, functional and translational studies, establishes SMAD4 as a key regulator of PCA progression in mice and humans.Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41292572
Collections
- SPH Scholarly Articles [6353]
Contact administrator regarding this item (to report mistakes or request changes)